)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
MannKind
MannKind (MNKD) investor relations material
MannKind Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 revenue rose 24% YoY to $101.9M; commercial product revenue increased to $45.0M, with Furoscix adoption and Afrezza pediatric demand supporting growth.
Nine-month revenue increased 27% to $301.4M; the five-year revenue CAGR was 42%.
Growth spans commercial products, United Therapeutics royalties and manufacturing, and DPI pipeline programs targeting lung diseases.
Financial highlights
Q3 GAAP net loss was $23.224M versus net income of $7.985M a year earlier; adjusted net loss was $3.615M versus adjusted net income of $22.447M.
Nine-month GAAP net loss was $58.874M versus net income of $21.811M; adjusted net loss was $10.408M versus adjusted net income of $57.977M.
Q3 commercial product sales were $45.0M versus $22.3M; royalties were $37.5M, up 12%, and collaborations and services were $19.4M, down 27%.
Nine-month commercial product revenue rose 90% to $120.9M; royalties rose 8% to $102.6M, and collaboration revenue was $180.5M.
Outlook and guidance
Q4 GAAP and non-GAAP profitability is expected, with record revenue; annual profitability is expected in 2027, though not necessarily in Q1.
Furoscix Q4 revenue is expected to exceed H1 2026 revenue; ReadyFlow adoption is expected to inform future dosage-form mix and margins.
Estimated cumulative collaboration revenue for 2027–2030 exceeds $1B, based on current assumptions and not intended as financial guidance.
A $15M ralinepag DPI milestone is anticipated in 2027; nintedanib DPI Phase 2 data are expected in H1 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MannKind
- IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification.MNKD
Chardan's 10th Annual Healthcare Conference - Afrezza pediatric launch, FUROSCIX ReadyFlow, and IPF 201 progress drive growth focus.MNKDH.C. Wainwright 28th Annual Global Investment Conference
- Q2 2026 revenue up 43% to $109.4M, driven by Afrezza pediatric and FUROSCIX launches.MNKDQ2 2026
- Nintedanib DPI showed strong safety and efficient lung delivery in IPF, supporting Phase 2 trials.MNKDStudy result
- FDA approved FUROSCIX ReadyFlow, enabling rapid at-home IV-equivalent diuretic therapy.MNKDFDA announcement
- Diversified growth, new launches, and pipeline advances set the stage for accelerated revenue and margin expansion.MNKDLeerink Global Healthcare Conference 2026
- Pediatric Afrezza approval and FUROSCIX auto-injector drive growth amid strong pipeline progress.MNKDJefferies Global Healthcare Conference 2026
- Q4 and FY 2025 revenues surged, driven by FUROSCIX and Afrezza, with major 2026 catalysts ahead.MNKDQ4 2025
- Q1 revenue up 18% to $78.4M, net income up 24%, driven by Tyvaso DPI and Afrezza growth.MNKDQ1 2025
Next MannKind earnings date
Q4 202626 Feb, 2027
MannKind
Next MannKind earnings date
Q4 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diabetes and pulmonary diseases. The company’s flagship product is an inhalable insulin used to manage blood sugar levels in adults with diabetes. MannKind is also exploring its proprietary Technosphere platform for the delivery of other therapeutic agents via inhalation, aiming to improve treatment options for various chronic conditions. The company is headquartered in Danbury, Connecticut, and its shares are listed on the NASDAQ.